Atomoxetine Capsules — Class II drug recall D-0239-2025
Ongoing recall by Glenmark Pharmaceuticals Inc., USA, reported 2025-02-26, distributed nationwide. CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
| Recall number | D-0239-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States |
| Recall initiated | 2025-01-29 |
| Classified | 2025-02-20 |
| Reported by FDA | 2025-02-26 |
| Distributed | Nationwide (US) |
| Quantity | 119,040 bottles |
| Reason classes | cgmp, specification failure |
| NDC | 16714-0755, 16714-0755-01, 16714-0756, 16714-0756-01, 16714-0757, 16714-0757-01, 16714-0758, 16714-0758-01, 16714-0759, 16714-0759-01, 16714-0760, 16714-0760-01, 16714-0761, 16714-0761-01 |
| Lot numbers | 19233227, 19233228, 19233757, 19234229, 19235090, 19241471, 19242180 |
| Expiration dates | 2025-07, 2025-08, 2025-09, 2025-11, 2026-03, 2026-05 |
Product
Atomoxetine Capsules, USP, 18 mg, 30 capsule bottles, Rx Only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Glenmark Pharmaceuticals Ltd., Goa, India, NDC 16714-756-01.
Reason for recall
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0239-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.